Second Quarter Report Q2-2026

Cessatech Operational highlights * Entered collaboration with Rigshospitalet to advance CT004 in paediatric patients Events after the reporting period * CHMP opinion received for KemSu/CT001; re-examination process initiated with EMA * CT001 ready for shipment to initial U.S. hospitals as launch activities commence Copenhagen, Denmark – 28 August 2026 - Cessatech A/S (“Cessatech” or the “Company”), a late-stage paediatric specialty company developing and commercializing hospital medicines for children, today announced the interim report for the second quarter of 2026, together with an update on key developments after the reporting period. The report is available on Cessatech’s website.

Second quarter financial results 2026 (1 April – 30 June) * Net revenue was KDKK 0 * Operating result was KDKK -3.469 * Net result was KDKK -2.773 * Cash at bank end of the period was KDKK 2.348 * Earnings per share* was DKK -0,15 * Solidity** was 77% *Earnings per share (DKK per share): Operating result divided by the average number of shares during the period. The total number of shares as of 30 June 2026 amounted to 18.576.437 shares, the average number of shares during the second quarter was 18.576.437 **Solidity: Total equity divided by total capital and liability